The company aims to combine the liquid nasal formulation and SPC-15’s novel protocol intended for the treatment and prevention of anxiety, PTSD and other stress-related disorders.

Data to Support Alzheimer’s StudyENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company ...

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders. Aug. 08, 2023 8:30 AM ET Silo Pharma, Inc. (SILO) ...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD Sep. 12, 2023 8:50 AM ET Silo Pharma, Inc. (SILO) Investigational New Drug (IND) submission to FDA on target ...

The Phase III MAPP trials, which drove the NDA, enrolled 221 PTSD patients. Patients participated in three eight-hour therapy sessions over 12 weeks and were randomised to receive either the ...

BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trialBNC210 Phase 2b PTSD trial on target for start in mid-2021 with ...

(2023-09-12 | NDAQ:SILO) Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree ...

--Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has advanced the formulation ...

Study data to determine potential delivery partners ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage ...